Japanese journal of clinical oncology
Real-world outcomes of prostate-specific membrane antigen-targeted radioligand therapy in Japanese patients with metastatic castration-resistant prostate cancer.
Yuki Enei, Takafumi Yanagisawa, Hidetoshi Kuruma, Chieko Okazaki, Ken Watanabe, Atsuya Okada, Nat Lenzo, Takahiro Kimura, Kenta Miki
Published: 202510.1093/jjco/hyaf179
Abstract
PURPOSE: Prostate-specific membrane antigen radioligand therapy (PSMA RLT) improves survival in metastatic castration-resistant prostate cancer (mCRPC). However, evidence in Japanese cohorts is limited. We evaluated the safety and efficacy of PSMA RL…
Preview only. Read the full abstract at the source